Compare ARCT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | OMER |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 844.6M |
| IPO Year | 2019 | 2008 |
| Metric | ARCT | OMER |
|---|---|---|
| Price | $15.98 | $17.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $24.11 | ★ $32.50 |
| AVG Volume (30 Days) | 1.4M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $82,031,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.77 | $233.22 |
| P/E Ratio | ★ N/A | $22.89 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.50 | $3.94 |
| 52 Week High | $24.14 | $19.65 |
| Indicator | ARCT | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 65.93 | 49.27 |
| Support Level | $6.47 | $10.16 |
| Resistance Level | $17.75 | $17.65 |
| Average True Range (ATR) | 1.37 | 0.82 |
| MACD | -0.24 | -0.45 |
| Stochastic Oscillator | 58.75 | 21.47 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.